Xenon’s 42.7% Seizure Reduction Spurs Biohaven Premarket Rally
Biohaven shares rose in premarket trading before retreating after Xenon’s Phase 3 X-TOLE2 study reported a placebo-adjusted median 42.7% reduction in monthly focal-onset seizures at 25 mg. Biohaven’s Opakalim (BHV-7000) is in two Phase 3 epilepsy trials and a Phase 2 major depressive disorder study.
1. Premarket Reaction to Xenon Seizure Data
Biohaven shares climbed in premarket to a session high after Xenon’s Phase 3 X-TOLE2 study reported a placebo-adjusted median 42.7% reduction in monthly focal-onset seizures at 25 mg. The stock pared gains and traded lower in the main session.
2. Biohaven Opakalim (BHV-7000) Pipeline
Opakalim (BHV-7000), Biohaven’s selective KV7.2/3 potassium channel activator, is undergoing two Phase 3 trials for focal and generalized epilepsy and a Phase 2 trial in major depressive disorder. A prior Phase 2 MDD proof-of-concept study did not meet its primary MADRS endpoint over six weeks.
3. Technical Indicators and Analyst Outlook
Shares sit 12.5% below their 20-day SMA and 16.7% below the 50-day SMA, with a 12-month decline of 64.95%. The RSI at 36.10 and MACD below its signal line point to bearish pressure. The stock has key resistance at $10.50 and support at $9.50, and analysts average a $30.36 target, ranging from $10.00 to $23.00.
4. Sector-driven Uptick After FDA Leadership Change
Broader biotech sector gains followed the departure of the FDA’s vaccines and gene therapies division head, driving Biohaven up 23% alongside peers, reflecting renewed investor confidence in regulatory prospects.